SCHEMBL522138

SCHEMBL522138

CSCOCc1ccccc1[C]=O

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9166919 0.83
SCHEMBL522409 0.82
SCHEMBL7672866 0.80 L3MBTL1 (0.34) FFAR1
SCHEMBL7677777 0.76 FFAR1 (0.47) FFAR1
SCHEMBL16097299 0.75 TSHR (0.56)
SCHEMBL522139 0.72 LMNA (0.40)
SCHEMBL113974 0.71 HTT (0.49)
SCHEMBL535892 0.71 GABRA1 (0.45) FFAR1
SCHEMBL442437 0.70 ALDH1A1 (0.52) FFAR1
SCHEMBL10814058 0.70 CYP1A2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029513-A1 Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules AGILENT TECHNOLOGIES, INC. 2010-02-04 US claimed
US-7576119-B2 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2009-08-18 US claimed
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2008-01-24 US claimed
US-7202264-B2 Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides ISIS PHARMACEUTICALS, INC. (US) 2007-04-10 US claimed
EP-1670810-A2 GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI Isis Pharmaceuticals, Inc. (US) 2006-06-21 EP claimed
US-20050208588-A1 Supports for oligomer synthesis ISIS PHARMACEUTICALS, INC. (US) 2005-09-22 US claimed
US-20050059066-A1 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini IONIS PHARMACEUTICALS, INC. 2005-03-17 US claimed
WO-2005023825-A2 GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI ISIS PHARMACEUTICALS, INC. (US) 2005-03-17 WO claimed
US-20050053981-A1 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini ISIS PHARMACEUTICALS, INC. 2005-03-10 US claimed
US-20040242897-A1 Universal support media for synthesis of oligomeric compounds ISIS PHARMACEUTICALS, INC. 2004-12-02 US claimed
WO-2000075157-A1 OLIGONUCLEOTIDE SYNTHESIS WITH LEWIS ACIDS AS ACTIVATORS ABBOTT LABORATORIES (US) 2000-12-14 WO claimed
US-5721350-A Deuterated nucleosides CHATTOPADHYAYA JYOTI (SE) 1998-02-24 US claimed
JP-H09510206-A 1997-10-14 JP claimed
US-5623068-A Synthesis of DNA using substituted phenylacetyl-protected nucleotides BECKMAN INSTRUMENTS, INC. (US) 1997-04-22 US claimed
EP-0749436-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1996-12-27 EP claimed
US-5574146-A Oligonucleotide synthesis with substituted aryl carboxylic acids as activators BECKMAN INSTRUMENTS, INC. (US) 1996-11-12 US claimed
EP-0725787-A1 ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF BECKMAN INSTRUMENTS, INC. (US) 1996-08-14 EP claimed
WO-1996006853-A1 ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF BECKMAN INSTRUMENTS, INC. (US) 1996-03-07 WO claimed
WO-1995024413-A1 COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1995-09-14 WO claimed
WO-1993025566-A1 DEUTERATED NUCLEOSIDES CHATTOPADHYAYA JYOTI (SE) 1993-12-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021224-A1 SUPPORTS FOR OLIGOMER SYNTHESIS ILK, NOP2, PFAS FFAR1 4870/4885
US-20100029513-A1 Methods And Compositions For Generating Mixtures Of Nucleic Acid Molecules POLM, RNGTT, POLN FFAR1 4584/4885
US-20050059066-A1 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini OGG1, UNG, PCNA FFAR1 4118/4885
US-20050053981-A1 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini OGG1, UNG, PCNA FFAR1 4118/4885
US-20050208588-A1 Supports for oligomer synthesis ILK, NOP2, PFAS FFAR1 4870/4885
US-20040242897-A1 Universal support media for synthesis of oligomeric compounds NEFM, POLRMT, POLM FFAR1 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.